However, despite promising results in a mouse model of liver fibrosis [328], clinical trials investigating the LOXL2 blocking antibody Simtuzumab in patients with NASH, human immunodeficiency virus (HIV), or HCV-associated liver fibrosis as well as primary sclerosing cholangitis gave only disappointing results with no effect on liver fibrosis [329,330,331]. The gene discussed is LOXL2; the disease is Hepatic fibrosis.